COMMUNIQUÉS West-GlobeNewswire

Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting

14/11/2024 - 22:45

Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden DALLAS, Nov. 14, [...]

Alvotech Reports Financial Results for the First Nine Months of 2024

13/11/2024 - 22:05

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 million Product revenues in the first nine months of 2024 [...]

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

13/11/2024 - 22:05

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, [...]

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

13/11/2024 - 22:05

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor [...]

Glass House Brands Reports Record Setting Third Quarter 2024 Financial Results

13/11/2024 - 22:05

- Glass House achieved record setting results for over 10 key metrics, including consolidated revenue and gross profit, wholesale biomass revenue, retail revenue, biomass production and cultivation cost per pound - [...]

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

13/11/2024 - 22:05

SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]

Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results

13/11/2024 - 22:05

Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC [...]

The Ensign Group to Present at the Stephens Annual Investment Conference on November 20, 2024

13/11/2024 - 22:05

SAN JUAN CAPISTRANO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

13/11/2024 - 22:05

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has [...]

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

13/11/2024 - 22:05

Generated $48.1 million in XDEMVY ® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare [...]

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

13/11/2024 - 22:05

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief [...]

STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

13/11/2024 - 22:05

HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

13/11/2024 - 22:05

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society for Immunotherapy of [...]

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

13/11/2024 - 22:05

BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today [...]

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

13/11/2024 - 22:05

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

13/11/2024 - 22:05

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 [...]

Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing

13/11/2024 - 22:05

Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Monrovia, CA, Nov. 13, 2024 (GLOBE [...]

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

13/11/2024 - 22:05

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and [...]

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13/11/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]